Therapeutic potential of the SARMs: Revisiting the androgen receptor for drug discovery

Expert Opinion on Investigational Drugs

Volumn 15, Issue 4, 2006, Pages 377-387

  Segal, Scott ^a   Narayanan, Ramesh ^a   Dalton, James T ^a  

^a GTx Inc   (United States)

Author keywords

Androgen; Hypogonadism; Muscle wasting; Osteoporosis; Steroid

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANABOLIC AGENT; ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; BMS 564929; CALCIUM; CORTICOSTEROID; ESTROGEN DERIVATIVE; HORMONE RECEPTOR AFFECTING AGENT; HYDANTOIN DERIVATIVE; LGD 2226; MEGESTROL ACETATE; OSTARINE; OXANDROLONE; PARATHYROID HORMONE; PRASTERONE; PROPIONAMIDE DERIVATIVE; PROSTAGLANDIN E1; PROSTAGLANDIN E2; QUINOLINONE DERIVATIVE; REGULATOR PROTEIN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TESTOSTERONE; TESTOSTERONE DERIVATIVE; TETRAHYDROQUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ALZHEIMER DISEASE; BONE GROWTH; BURN; CANCER THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DYSLIPIDEMIA; EDEMA; HUMAN; HYPOGONADISM; KIDNEY FAILURE; LIVER TOXICITY; MOOD DISORDER; MUSCLE ATROPHY; MUSCLE GROWTH; NONHUMAN; OSTEOPOROSIS; OSTEOSARCOMA; PARKINSON DISEASE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TISSUE METABOLISM; VIRILIZATION; WOUND HEALING;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; DRUG DESIGN; HUMANS; MALE; RECEPTORS, ANDROGEN;

EID: 33645703903     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.4.377     Document Type: Review

References (84)

1. EVANS RM: The steroid and thyroid hormone receptor superfamily. Science (1988) 240(4854):889-895.
2. TSAI MJ, O'MALLEY BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann. Rev. Biochem. (1994) 63:451-486.
3. RIGGS BL, HARTMANN LC: Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N. Engl. J. Med. (2003) 348(7):618-629.
4. DALTON JT, MUKHERJEE A, ZHU Z, KIRKOVSKY L, MILLER DD: Discovery of nonsteroidal androgens. Biochem. Biophys. Res. Commun. (1998) 244(1):1-4.
5. LINK JT, SORENSEN B, PATEL J et al.: Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators. J. Med. Chem. (2005) 48(16):5295-5304.
6. TABATA Y, IIZUKA Y, SHINEI R et al.: CP8668, a novel orally active nonsteroidal progesterone receptor modulator with tetrahydrobenzindolone skeleton. Eur. J. Pharmacol. (2003) 461(1):73-78.
7. BUIJSMAN RC, HERMKENS PH, VAN RIJN RD, STOCK HT, TEERHUIS NM: Non-steroidal steroid receptor modulators. Curr. Med. Chem. (2005) 12(9):1017-1075.
8. BLUMBERG B, EVANS RM: Orphan nuclear receptors-new ligands and new possibilities. Genes Dev. (1998) 12(20):3149-3155.
9. LUBAHN DB, JOSEPH DR, SAR M et al.: The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol. Endocrinol. (1988) 2(12):1265-1275.
10. TAN JA, JOSEPH DR, QUARMBY VE et al.: The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein. Mol. Endocrinol. (1988) 2(12):1276-1285.
11. JENSTER G, VAN DER KORPUT HA, VAN VROONHOVEN C, VAN DER KWAST TH, TRAPMAN J, BRINKMANN AO: Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. (1991) 5(10):1396-1404.
12. BEATO M: Gene regulation by steroid hormones. Cell (1989) 56(3):335-344.
13. BEVAN CI., HOARE S, CLAESSENS F, HEERY DM, PARKER MG: The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol. Cell Biol. (1999) 19(12):8383-8392.
14. ALEN P, CLAESSENS F, VERHOEVEN G, ROMBAUTS W, PEETERS B: The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol. Cell Biol. (1999) 19(9):6085-6097.
15. SIMENTAL JA, SAR M, LANE MV, FRENCH FS, WILSON EM: Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem. (1991) 266(1):510-518.
16. KATO S, ENDOH H, MASUHIRO Y et al.: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science (1995) 270(5241):1491-1494.
17. O'MALLEY BW, TSAI MJ: Molecular pathways of steroid receptor action. Biol. Reprod. (1992) 46(2):163-167.
18. YLIKOMI T, BOCQUEL MT, BERRY M, GRONEMEYER H, CHAMBON P: Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. EMBO J. (1992) 11(10):3681-3694.
19. 2-terminal and carboxyl-terminal sequences. J. Biol. Chem. (1994) 269(18):13115-13123.
20. SAPORITA AJ, ZHNAG Q, NAVAI N et al.: Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J. Biol. Chem. (2003) 278(43):41998-42005.
21. JEWELL CM, SHAHAM Y, HOMBERG JR et al.: Immunocytochemical analysis of hormone mediated nuclear translocation of wild type and mutant glucocorticoid receptors. J. Steroid Biochem. Mol. Biol. (1995) 55(2):135-146.
22. SIMEONI S, MANCINI MA, STENOIEN DL et al.: Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Hum. Mol. Genet. (2000) 9(1):133-144.
23. FANG Y, FLISS AE, ROBINS DM, CAPLAN AJ: Hsp90 regulates androgen receptor hormone binding affinity in vivo. J. Biol. Chem. (1996) 271(45):28697-28702.
24. CARDOZO CP, MICHAUD C, OST MC et al.: C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Arch. Biochem. Biophys. (2003) 410(1):134-140.
25. PAJONK F, VAN OPHOVEN A, McBRIDE WH: Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res. (2005) 65(11):4836-4843.
26. 2-/ carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J. Biol. Chem. (1998) 273(1):92-101.
27. KEMPPAINEN JA, LANGLEY E, WONG CI, BOBSEINE K, KELCE WR, WILSON EM: Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol. Endocrinol. (1999) 13(3):440-454.
28. SATHYA G, CHANG CY, KAZMIN D, COOK CE, McDONNELL DP: Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res. (2003) 63(22):8029-8036.
29. ONATE SA, TSAI SY, TSAI MJ, O'MALLEY BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science (1995) 270(5240):1354-1357.
30. SPENCER TE, JENSTER G, BURCIN MM et al.: Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (1997) 389(6647):194-198.
31. CULIG Z, COMUZZI B, STEINER H, BARTSCH G, HOBISCH A: Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. (2004) 92(4):265-271.
32. RAY MR, WAFA LA, CHENG H et al.: Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int. J. Cancer (2006) 118(5):1108-1119.
33. LUTZ LB, JAMNONGJIT M, YANG WH, JAHANI D, GILL A, HAMMES SR: Selective modulation of genomic and nongenomic androgen responses by androgen receptor ligands. Mol. Endocrinol. (2003) 17(6):1106-1116.
34. UNNI E, SUN S, NAN B et al.: Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. (2004) 64(19):7156-7168.
35. KOUSTENI S, BELLIDO T, PLOTKIN LI et al.: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 104(5):719-730.
36. ESTRADA M, ESPINOSA A, MULLER M, JAIMOVICH E: Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells. Endocrinology (2003) 144(8):3586-3597.
37. MATSUMOTO T, et al.: Androgen receptor functions from reverse genetic models. J. Steroid Biochem. Mol. Biol. (2003) 85(2-5):95-99.
38. IKEDA Y, AIHARA K, SATO T et al.: Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J. Biol. Chem. (2005) 280(33):29661-29666.
39. KAWANO H, SATO T, YAMADA T et al.: Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. USA (2003) 100(16):9416-9421.
40. OETTEL M: Testosterone metabolism, dose-response relationships and receptor polymorphisms: selected pharmacological/toxicological considerations on benefits versus risks of testosterone therapy in men. Aging Male (2003) 6(4):230-256.
41. HARKIN KR, COWAN LA, ANDREWS GA et al.: Hepatotoxicity of stanozolol in cats. J. Am. Vet. Med. Assoc. (2000) 217(5):681-684.
42. BARQAWI A, CRAWFORD ED: Testosterone replacement therapy and the risk of prostate cancer: a perspective view. Int. J. Impot. Res. (2005) 17(5):462-463.
43. GOOREN L: Hormone treatment of the adult transsexual patient. Horm. Res. (2005) 64(Suppl. 2):31-36.
44. GAO W, REISER PJ, COSS CC et al.: Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 146(11):4887-4897.
45. CHEN J, HWANG DJ, BOHL CE et al.: A selective androgen receptor modulator for hormonal male contraception. J. Pharmacol. Exp. Ther. (2005) 312(2):546-553.
46. GAO W, KEARBEY JD, NAIR VA et al.: Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5α-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology (2004) 145(12):5420-5428.
47. HAMANN LG: Discovery and preclinical profile of a highly potent and muscle selective androgen receptor modulator (SARM). 227th National Meeting of the American Chemical Society Medicinal Chemistry Division, Anaheim, USA (2004).
48. HANADA K, FURUYA K, YAMAMOTO N et al.: Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol. Pharm. Bull. (2003) 26(11):1563-1569.
49. ROSEN J, NEGRO-VILAR A: Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J. Musculoskelet. Neuronal, Interact. (2002) 2(3):222-224.
50. YIN D, GAO W, KEARBEY JD et al.: Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. (2003) 304(3):1334-1340.
51. MINER JN, BURNETT K, CHANG W et al.: Steroid receptor modulators: approaches to selectivity for androgen receptor. Keystone Symposium on Selective Nuclear Receptor Modulators, Breckenridge, USA (18-22 September 2005).
52. DARBY E, ANAWALT BD: Male hypogonadism: an update on diagnosis and treatment. Treat. Endocrinol. (2005) 4(5):293-309.
53. MORALES A, HEATON JP, CARSON CC III: Andropause: a misnomer for a true clinical entity. J. Urol, (2000) 163(3):705-712.
54. GAYLIS FD, LIN DW, IGNATOFF JM, AMLING CL, TUTRONE RF, COSGROVE DJ: Prostate cancer in men using testosterone supplementation. J. Urol. (2005) 174(2):534-538 (Discussion 538).
55. PARSONS JK, CARTER HB, PLATZ EA, WRIGHT EJ, LANDIS P, METTER EJ: Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol. Biomarkers Prev. (2005) 14(9):2257-2260.
56. BANCROFT J, CAWOOD EH: Androgens and the menopause; a study of 40-60-year-old women. Clin. Endocrinol. (Oxf.) (1996) 45(5):577-587.
57. BRAUNSTEIN GD, SUNDWALL DA, KATZ M et al.: Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch. Intern. Med. (2005) 165(14):1582-1589.
58. JOHANNSSON G, BURMAN P, WIREN L et al.: Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J. Clin. Endocrinol. Metab. (2002) 87(5):2046-2052.
59. BUSTER JE, KINGSBERG SA, AGUIRRE O et al.: Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet. Gynecol. (2005) 105(5 Part 1):944-952.
60. ORR R, FIATARONE SINGH M: The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs (2004) 64(7):725-750.
61. DEMLING RH, SEIGNE P: Metabolic management of patients with severe burns. World J. Surg. (2000) 24(6):673-680.
62. PEREIRA C, MURPHY K, JESCHKE M, HERNDON DN et al.: Post burn muscle wasting and the effects of treatments. Int. J. Biochem. Cell Biol. (2005) 37(10):1948-1961.
63. DEMLING RH, DE SANTI L: Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid. Burns (2003) 29(8):793-797.
64. JOHANSEN KL, MULLIGAN K, SCHAMBELAN M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. J. Am. Med. Assoc. (1999) 281(14):1275-1281.
65. LANGER CJ, HOFFMAN JP, OTTERY FD: Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition (2001) 17(Suppl. 1):S1-S20.
66. STUART B, DOSHI JA, BRIESACHER B, WROBEL MV, BAYSAC F: Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease. Clin. Ther. (2004) 26(10):1688-1699.
67. DEBIGARE R, MARQUIS K, COTE CH et al.: Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest (2003) 124(1):83-89.
68. LAGHI F, ANTONESCU-TURCU A, COLLINS E et al.: Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. Am. J. Respir. Crit. Care Med. (2005) 171(7):728-733.
69. BOONEN S, VANDERSCHUEREN D, CHENG XG et al.: Age-related (type II) femoral neck osteoporosis in men: biochemical evidence for both hypovitaminosis D- and androgen deficiency-induced bone resorption. J. Bone Miner. Res. (1997) 12(12):2119-2126.
70. McCABE LD, MARTIN BR, McCABE GP et al.: Dairy intakes affect bone density in the elderly. Am, J. Clin. Nutr. (2004) 80(4):1066-1074.
71. BENITO M, VASILIC B, WEHRLI FW et al.: Effect of testosterone replacement on trabecular architecture in hypogonadal men. J. Bone Miner. Res. (2005) 20(10):1785-1791.
72. MITLAK BH: Parathyroid hormone as a therapeutic agent. Curr. Opin. Pharmacol. (2002) 2(6):694-699.
73. DEMLING RH: Oxandrolone, an anabolic steroid, enhances the healing of a cutaneous wound in the rat. Wound Repair Regen. (2000) 8(2):97-102.
74. DEMLING RH, DE SANTI L: Involuntary weight loss and the nonhealing wound: the role of anabolic agents. Adv. Wound Care (1999) 12(Suppl. 1):1-14 (Quiz 15-16).
75. SPUNGEN AM, KOEHLER KM, MODESTE-DUNCAN R, RASUL M, CYTRYN AS, BAUMAN WA: 9 clinical cases of nonhealing pressure ulcers in patients with spinal cord injury treated with an anabolic agent: a therapeutic trial. Adv. Skin Wound Care (2001) 14(3):139-144.
76. WANG C, CUNNINGHAM G, DOBS A et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. (2004) 89(5):2085-2098.
77. SEIDMAN SN, ARAUJO AB, ROOSE SP, McKINLAY JB: Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol. Psychiatry (2001) 50(5):371-376.
78. POPE HG Jr, COHANE GH, KANAYAMA G, SIEGEL AJ, HUDSON JI: Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160(1):105-111.
79. OKUN MS, WALTER BL, McDONALD WM et al.: Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson's disease. Arch. Neurol. (2002) 59(11):1750-1753.
80. MARTIGNONI E, GODI L, PACCHETTI C et al.: Is seborrhea a sign of autonomic impairment in Parkinson's disease? J. Neural Transm. (1997) 104(11-12):1295-1304.
81. HOGERVORST E, WILLIAMS J, BUDGE M, BARNETSON L, COMBRINCK M, SMITH AD: Serum total testosterone is lower in men with Alzheimer's disease. Neuro. Endocrinol. Lett. (2001) 22(3):163-168.
82. LEHMANN DJ, HOGERVORST E, WARDEN DR, SMITH AD, BUTLER HT, RAGOUSSIS J: The androgen receptor CAG repeat and serum testosterone in the risk of Alzheimer's disease in men. J. Neurol. Neurosurg. Psychiatry (2004) 75(1):163-164.
83. CHERRIER MM, MATSUMOTO AM, AMORY JK et al.: Testosterone improves spatial memory in men with Alzheimer's disease and mild cognitive impairment. Neurology (2005) 64(12):2063-2068.
84. CHRISTIANSEN RG, BELL MR, D'AMBRA TE et al.: Antiandrogenic steroidal sulfonylpyrazoles. J. Med. Chem. (1990) 33(8):2094-2100.